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Abstract
OBJECTIVE.—To describe pathogen distribution and antimicrobial resistance patterns for 
healthcare-associated infections (HAIs) reported to the National Healthcare Safety Network 
(NHSN) from pediatric locations during 2011–2014.
METHODS.—Device-associated infection data were analyzed for central line-associated 
bloodstream infection (CLABSI), catheter-associated urinary tract infections (CAUTI), ventilator-
associated pneumonia (VAP), and surgical site infection (SSI). Pooled mean percentage resistance 
was calculated for a variety of pathogen-antimicrobial resistance pattern combinations and was 
stratified by location for device-associated infections (neonatal intensive care units [NICUs], 
pediatric intensive care units [PICUs], pediatric oncology and pediatric wards) and by surgery type 
for SSIs.
RESULTS.—From 2011 to 2014, 1,003 hospitals reported 20,390 pediatric HAIs and 22,323 
associated pathogens to the NHSN. Among all HAIs, the following pathogens accounted for more 
than 60% of those reported: Staphylococcus aureus (17%), coagulase-negative staphylococci 
(17%), Escherichia coli (11%), Klebsiella pneumoniae and/or oxytoca (9%), and Enterococcus 
faecalis (8%). Among device-associated infections, resistance was generally lower in NICUs than 
in other locations. For several pathogens, resistance was greater in pediatric wards than in PICUs. 
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The proportion of organisms resistant to carbapenems was low overall but reached approximately 
20% for Pseudomonas aeruginosa from CLABSIs and CAUTIs in some locations. Among SSIs, 
antimicrobial resistance patterns were similar across surgical procedure types for most pathogens.
CONCLUSION.—This report is the first pediatric-specific description of antimicrobial resistance 
data reported to the NHSN. Reporting of pediatric-specific HAIs and antimicrobial resistance data 
will help identify priority targets for infection control and antimicrobial stewardship activities in 
facilities that provide care for children.
Healthcare-associated infections (HAIs) cause serious health consequences for patients and 
result in prolonged hospitalizations and increased healthcare expenditures, particularly when 
the causative microorganisms are antibiotic resistant (AR).1-7 Pediatric hospital patients are 
especially vulnerable to adverse outcomes from AR infections due to factors such as 
immature immune systems, acquired or congenital immunodeficiencies, need for chronic 
parenteral nutrition, and congenital anomalies.8 The unique impact HAIs have on pediatric 
patients is underscored by the fact that rates of device-associated infections are higher in 
some pediatric unit types than in corresponding adult units, despite a lower device utilization 
ratio.9 A recent analysis of device-associated infection data has demonstrated a decline in 
the incidence of central line-associated bloodstream infections (CLABSIs) and ventilator-
associated pneumonia infections (VAPs) in pediatric units between 2007 and 2012.6 
However, data specifically describing antibiotic resistance among pathogens associated with 
pediatric device-associated infections and surgical site infections (SSIs) are lacking.10
Providing data to inform HAI and antibiotic resistance prevention efforts is an essential 
function of the Centers for Disease Control and Prevention’s (CDC’s) National Healthcare 
Safety Network (NHSN). Although NHSN reports describing HAI and antibiotic resistance 
data in the United States have been published,11-13 these reports did not provide separate 
results for adult and pediatric inpatient locations. We used methods similar to those of prior 
NHSN reports to describe the prevalence of antimicrobial resistance among HAIs reported 
from pediatric locations.
METHODS
HAI Reporting
We used data from CLABSIs, catheter-associated urinary tract infections (CAUTIs), VAPs, 
and SSIs that (1) occurred from 2011 to 2014 in pediatric units, (2) met NHSN HAI 
surveillance definitions in place at that time, and (3) were reported to NHSN by December 
16, 2015. Analyses of datasets from later months in this period may yield different results 
because NHSN users are able to edit their data as needed. NHSN surveillance methodology 
has been reported previously.11, 14-18 Pediatric HAIs can be reported to NHSN from acute-
care hospitals, long-term acute-care hospitals (LTACHs), and inpatient rehabilitation 
facilities (IRFs); facility type is self-identified by facilities during initial enrollment into the 
NHSN. Neonatal intensive care units (NICUs) included in this report are those classified by 
NHSN CDC location codes as level II/III, a combined nursery housing both level II and III 
newborns and infants, or level III, a NICU with personnel and equipment to provide 
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continuous life support and comprehensive care for extremely high-risk newborn infants and 
those with complex and critical illnesses.
NHSN HAI surveillance protocols provide procedures for attributing device-associated 
infections (CLABSIs, CAUTIs, and VAPs) to CDC location types and SSIs to CDC 
operative procedure categories.14-17 We included device-associated infection data reported 
from pediatric locations in long-term acute care (LTAC) and inpatient rehabilitation facilities 
(IRFs). Because HAIs were not included in the Centers for Medicaid & Medicare Services 
Quality Reporting Programs for LTAC hospitals and IRFs until October 2012,19, 20 data 
from these facility types might not have been reported for the entire 4-year period. Also, 
VAP data reporting by NICUs ended in December 201316; this report includes NICU VAP 
data from 2011 to 2013 and VAP data from pediatric critical care locations for all 4 years. 
CAUTIs are not reported by NICUs.
Laboratory Reporting
For each HAI, data contributors were able to report up to 3 causative pathogens. For selected 
pathogens, the NHSN also required users to report antimicrobial susceptibility information. 
Clinical laboratories in facilities reporting data to NHSN were expected to use Clinical and 
Laboratory Standards Institute standards for antimicrobial susceptibility testing in place at 
the time. Bacterial susceptibility results were reported categorically to NHSN as 
“susceptible” (S), “intermediate” (I), “resistant” (R), or “not tested” (N).
We grouped pathogens and defined antimicrobial resistance according to methods described 
previously.13 Staphylococcus aureus was defined as methicillin-resistant (MRSA) if an 
isolate was reported to be R to oxacillin, methicillin, and/or cefoxitin. Enterococcal species 
were defined as ampicillin resistant if an isolate was reported to be I or R to ampicillin, and 
vancomycin resistant if reported to be R to vancomycin. Pseudomonas aeruginosa was 
defined as resistant to extended-spectrum cephalosporins (ESCs) if an isolate was reported 
as I or R to ceftazidime or cefepime; fluoroquinolone resistant if an isolate was reported as I 
or R to ciprofloxacin or levofloxacin; and aminoglycoside resistant if an isolate was reported 
as I or R to gentamicin, amikacin, or tobramycin. Escherichia coli was defined as 
fluoroquinolone resistant if an isolate was reported to be I or R to ciprofloxacin, 
levofloxacin, or moxifloxacin. Enterobacteriaceae were defined as ESC resistant if an isolate 
was reported as I or R to ceftazidime, cefepime, ceftriaxone, or cefotaxime and as 
aminoglycoside resistant if an isolate was reported as I or R to gentamicin, amikacin, or 
tobramycin. Selected gram-negative pathogens were defined as carbapenem-resistant if an 
isolate was reported to be I or R to imipenem, meropenem, or doripenem, as these were the 
surveillance definitions for NHSN in 2011–2014.13 Because the classification “susceptible-
dose dependent” (S-DD) is used in place of I for azole antifungals (eg, fluconazole), 
Candida spp were defined as fluconazole resistant if an isolate was reported to be S-DD or R 
to fluconazole.
Criteria for defining multidrug resistance were similar to published interim standard 
definitions.13,21 To be defined as multidrug-resistant (MDR), a gram-negative pathogen must 
have been reported to be I or R to at least 1 agent in 3 or more antimicrobial categories. 
MDR categories included ESCs, fluoroquinolones, aminoglycosides, and carbapenems (all 
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organisms); piperacillin or piperacillin/tazobactam (Enter-obacteriaceae and P. aeruginosa); 
and ampicillin/sulbactam (Acinetobacter spp).
Statistical Analysis
Data were analyzed with SAS software, version 9.3 (SAS Institute, Cary, NC). For analyses 
of device-associated infections, pediatric or neonatal NHSN inpatient location types were 
grouped into 4 mutually exclusive categories: NICUs, pediatric intensive care units (PICUs), 
pediatric oncology wards, and pediatric wards (eg, medical, surgical, and step-down units). 
Absolute frequencies and distributions of reported HAIs or pathogens were calculated by 
hospital type, hospital size, HAI, surgery, and location type where applicable.
For device-associated infections, the most common 15 pathogens for each infection type–
location combination were identified and ranked. Similarly, for SSIs the 15 most common 
pathogens were ranked overall and by type of surgical procedure.
The percentage of pathogens tested for susceptibility (sum of pathogens tested for 
susceptibility, divided by the sum of total pathogens isolated, multiplied by 100) was 
calculated for each pathogen–antimicrobial class combination. Pooled mean percent 
resistance was calculated for each pathogen–antimicrobial combination (sum of pathogens 
that tested resistant, divided by the sum of pathogens tested for susceptibility, multiplied by 
100), for each HAI or type of surgical procedure, and for device-associated infections, 
stratified by pediatric location type. Pooled mean percent resistance was not calculated for 
any resistance phenotype where fewer than 20 pathogens were tested.13
Statistical comparisons of antimicrobial resistance differences between locations or 
procedure types are beyond the scope of this report. Only the absolute differences in 
resistance percentages are reported and discussed, so this report does not provide definitive 
conclusions regarding resistance differences between locations.
RESULTS
Distribution of Pediatric Healthcare-Associated Infections by Hospital, Surgical Procedure, 
and Location Types
From 2011 to 2014, 1,003 hospitals reported 20,390 HAIs to NHSN from pediatric units. Of 
these, the most frequent hospital type was general acute care, which comprised 88% of 
facilities that reported 62% of HAIs. Children’s hospitals comprised only 7% of facilities but 
reported 33% of HAIs. Hospitals with > 200 beds represented 74% of reporting facilities and 
reported 91% of HAIs (Table 1). Most HAIs reported (69%) were CLABSIs. A description 
of the number of events and pathogens reported by HAI and surgery type can be found in 
Tables 2 and 3. Device-associated infection pathogen distribution by inpatient location type 
and SSI pathogens by surgical type are located in Tables S1-S4 and Table S5 of the online 
supplement, respectively.
Pathogen Distribution
Across HAI types, 22,323 pathogens were reported. Overall, the most common pathogens 
were S. aureus (17%) and coagulase-negative staphylococci (17%), followed by E. coli 
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(11%) and K. pneumoniae/oxytoca (9%). Pathogen rankings varied between HAI types. 
Staphylococcal species were the most frequent for CLABSI (coagulase-negative 
staphylococci), SSI (S. aureus), and VAP (S. aureus), but E. coli was the most frequent 
CAUTI pathogen and ranked second among SSI pathogens. P. aeruginosa was the second 
most frequent pathogen reported for both CAUTI and VAP (Table 4).
Among 15,538 CLABSI pathogens, 51% were reported from NICUs, 23% from PICUs, 
15% from oncology units, and 11% from pediatric wards. Staphylococcus aureus and 
coagulase-negative staphylococci were the most frequently reported CLABSI pathogens in 
critical care locations. In oncology wards, viridans group streptococci (15%) and K. 
pneumoniae/oxytoca (12%) were the 2 most common pathogens reported; K. pneumoniae/
oxytoca was the most common CLABSI pathogen in pediatric ward locations (15%) (Table 
S2, online supplement).
Among 2,366 CAUTI pathogens, 83% were reported by PICUs and 15% were reported by 
pediatric wards. Pathogen distribution was similar between these 2 locations: E. coli and P. 
aeruginosa were the first and second most common pathogens for both locations, 
respectively, and K. pneumoniae/oxytoca, Enterobacter spp, and C. albicans were among the 
5 most common pathogens in both locations (Table S3, online supplement).
Among 1,366 VAP pathogens, 63% were reported from NICUs and 37% from PICUs. 
Staphylococcus aureus, P. aeruginosa, K. pneumoniae/oxytoca, and Enterobacter spp were 
the 4 most common pathogens in both location types. Streptococcus pneumoniae ranked 
fifth in PICUs, and E. coli ranked fifth in NICUs (Table S4, online supplement).
Of the 3,053 SSI pathogens reported, S. aureus was the most common pathogen overall 
(22%) and for orthopedic surgery SSIs (39%) and cardiac surgery SSIs (55%), and S. aureus 
was the second most common for neurological surgery SSIs (28%). Coagulase-negative 
staphylococci were the most common pathogen for neurological surgery SSIs (31%). 
Escherichia coli was the most common pathogen for abdominal surgery SSIs (28%) and the 
second most common overall (18%) (Table S5, online supplement).
Percent Resistance by HAI Type
For almost all pathogen-antibiotic combinations reported for CLABSIs, resistance was 
generally lower in NICUs than in other location types. Conversely, resistance was highest in 
oncology locations for multiple pathogen–antibiotic combinations, including ampicillin and 
vancomycin resistance for Enterococcus faecium; ESC and multidrug resistance for E. coli 
and K. pneumoniae/oxytoca; and fluoroquinolone resistance for E. coli. Resistance to 
carbapenems was infrequent (<4%) among Enterobacteriaceae in all locations. Fluconazole 
resistance was infrequent (<4%) for Candida albicans and C. parapsilosis, but it did reach 
41% for other Candida spp in oncology wards. However, no more than 50% of Candida spp 
isolates were tested in any location. For P. aeruginosa, resistance was highest for all 
pathogen–antibiotic combinations in pediatric wards. In addition, resistance was higher in 
pediatric wards than PICUs for S. aureus, E. faecalis, and E. coli, for all pathogen-antibiotic 
combinations evaluated (Table 5).
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For CAUTIs, resistance was higher in pediatric wards than PICUs for most pathogen–
antibiotic combinations. The percentage of E. coli and P. aeruginosa resistant to 
fluoroquinolones and of K. pneumoniae/oxytoca resistant to ESCs was approximately two-
fold higher in pediatric wards than PICUs. Overall, carbapenem resistance was infrequent 
(<4%), but on pediatric wards, 13% of P. aeruginosa isolates were carbapenem resistant. The 
proportion of E. faecalis resistant to vancomycin was 15% in pediatric wards compared to 
1% in PICUs (Table 6).
For VAPs, among K. pneumoniae/oxytoca and P. aeruginosa, resistance was higher overall in 
PICUs than in NICUs. In PICUs, >10% of K. pneumoniae/oxytoca and P. aeruginosa were 
resistant to carbapenems (Table 7).
For SSIs, percent of pathogens resistant to ESCs was lower for E. coli, P. aeruginosa, and K. 
pneumoniae/oxytoca (range, 4%−16%) and higher for Enterobacter spp (range, 22%−35%) 
across types of surgical procedures. Carbapenem resistance was highest among P. aeruginosa 
isolates causing SSIs due to abdominal surgery (7%). The proportion of methicillin-resistant 
S. aureus was similar among infections due to abdominal, orthopedic, and neurological 
surgery types, ranging from 26% in neurological procedures to 31% in abdominal 
procedures (Table 8).
DISCUSSION
This report is the first pediatric-specific description of antimicrobial resistance data reported 
to the NHSN, and it addresses a critical need for the pediatric infectious disease and 
infection control communities.10,22-26 Most previous studies describing pathogens and 
antimicrobial resistance among pediatric HAIs have come from single institutions, whereas 
the data presented here represent approximately 1,000 healthcare facilities across the United 
States.27 Furthermore, this report complements previous publications of pediatric NHSN 
data6, 9, 13, 28 by including both pathogen distribution and resistance data from pediatric 
critical care, oncology and pediatric ward locations to inform infection prevention and 
antimicrobial stewardship activities.
The pathogen distribution among NICU device-associated infections reported to NHSN 
between 2006 and 2008 was reported previously28; since that report, NHSN data have shown 
changes in the NICU CLABSI pathogen distribution. Coagulase-negative staphylococci 
(28.0% of 2,378 reported pathogens) and S. aureus (28.0%) have remained the 2 most 
common pathogens (28.1% and 24.9% of 7,842 reported pathogens, respectively). 
Previously Candida spp were the third most common CLABSI pathogens at 13.0%, but 
when data were pooled across reported species in this report, the proportion decreased to 
7.0% (1,192 reported Candida spp pathogens). For VAPs, in 2006–2008, the most common 
pathogen was P. aeruginosa (16.1% of 830 reported pathogens) followed closely by S. 
aureus (15.8%). In the current report, S. aureus was the most common (24.2% of 860 
reported pathogens).
The most recent NHSN antimicrobial resistance report13 represents data from all patient 
locations, and most of those data are from adult patients, who have often accumulated 
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numerous healthcare and antibiotic exposures over many years and, therefore not 
surprisingly, tend to have HAIs caused by more resistant pathogens. Our report demonstrates 
that resistance was lower among pathogens causing pediatric HAIs than in the combined 
data. For most pathogens and device-associated infection types, carbapenem resistance was 
lower in NICUs than in PICUs, oncology wards, and pediatric wards, perhaps reflecting a 
combination of patient age and the relative lack of cumulative antibiotic exposure among 
NICU patients compared to pediatric patients in other locations. Infections due to 
carbapenem-resistant organisms primarily affect patients with healthcare exposures, are 
associated with high mortality, and have been identified as emerging public health threats.
29-32
 Fortunately, our data show that prevalence overall remains low among pediatric 
patients, although others have shown increases in recent years, with children who are 
critically ill disproportionately affected.31,33
An unexpected result of this analysis was the higher rates of resistance for select pathogen-
antibiotic combinations, including P. aeruginosa (CLABSIs and CAUTIs) and E. coli 
(CAUTIs), reported from pediatric wards compared with from PICUs (and even oncology in 
some instances). Potential explanations include the possibility that patient characteristics and 
treatments in some pediatric ward locations pose increased risks for infections with resistant 
pathogens. Although device utilization typically is lower in pediatric wards than in critical 
care units, children in some ward locations may be treated for complex medical conditions 
that call for high indwelling device usage9 or frequent antibiotic usage, placing those 
children at particular risk for device-associated infections with resistant pathogens. For 
example, pediatric patients with short gut syndrome, who are dependent upon parenteral 
nutrition, are at high risk for recurrent central line infections and thus may have higher 
cumulative antibiotic exposure than even some critical care and oncology patients.34-37 For 
such patients, pathogens causing CLABSIs may be more likely to be antibiotic resistant. 
Other potential explanations include differences in infection control practices or 
opportunities for transmission in pediatric ward locations compared to critical care or 
oncology locations. In addition, it is possible that facilities reporting data to NHSN from 
pediatric wards may have higher levels of overall antibiotic resistance than facilities only 
reporting data to NHSN from critical care or oncology locations. Testing this hypothesis is 
beyond the scope of this paper.
Sparse data for some pathogen–location combinations are another limitation. When the 
number of reported pathogens is comparatively small for specific locations, between-
location comparisons are challenging. Sparse data also limit or preclude meaningful 
comparisons over time. Increased reporting of HAIs to NHSN from pediatric locations 
would improve the value of these data. Also, facilities select the locations and HAIs to report 
to NHSN, so differences in the number of events by HAI or location type may not reflect 
true differences in the actual frequency of events. We hope that reporting will increase over 
time, enhancing the representativeness and utility of these data.
Variations in laboratory reporting and testing practices are another study limitation. 
Antimicrobial susceptibility data are reported to NHSN categorically according to 
interpretation (i.e., without information on minimum inhibitory concentrations); therefore, 
any variability in reporting that exists between facilities as well as any changes in testing and 
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reporting practices over time cannot be assessed. Finally, data reported for most isolates 
indicated resistance, but when less than 70% of reported isolates are tested for resistance to a 
particular antibiotic, caution should be used when interpreting resistance data for that 
pathogen–antibiotic combination.13
This report presents pediatric antimicrobial resistance data that can be used as a baseline for 
comparison with future reports. Pathogens associated with HAIs vary in their mode and risk 
of transmission to patients as well as the mechanisms through which resistance is acquired. 
The differences in antimicrobial resistance seen in this report may indicate priority areas for 
prevention work. Overall, lower antimicrobial resistance rates for most pediatric HAIs 
compared to previously published data on adult HAIs highlight the opportunity for the 
pediatric healthcare community to pursue novel policies and practices to protect their 
patients from the acquisition and transmission of highly resistant organisms while these 
events remain uncommon. NHSN data have the potential to play an important role in 
monitoring and evaluation of these endeavors.
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TABLE 1.
Characteristics of Hospitals Reporting Pediatric Healthcare-Associated Infections (HAIs) to the National 
Healthcare Safety Network (NHSN), 2011–2014
Hospitals Reportinga
(n = 1,003)
HAIs Reported
(n = 20,390)
Characteristic No. % No. %
Hospital Type
 General 883 88.0 12,630 61.9
 Children’s 73 7.3 6,713 32.9
 Critical access 11 1.1 13 0.1
 Women’s and children’s 9 0.9 670 3.3
 Women’s 7 0.7 111 0.5
 Rehabilitationb 5 0.5 9 <0.1
 Military 4 0.4 65 0.3
 Orthopedic 4 0.4 8 <0.1
 Oncology 3 0.3 147 0.7
 Surgical 3 0.3 23 0.1
 Psychiatric 1 0.1 1 <0.1
Hospital Size
 ≤50 beds 48 4.8 183 0.9
 51–200 beds 215 21.4 1,632 8.0
 201–500 beds 512 51.0 9,694 47.5
 ≥501 beds 228 22.7 8,881 43.6
a
Reported at least 1 HAI between 2011 and 2014.
b
Includes free-standing rehabilitation facilities only. No inpatient rehabilitation facilities within acute-care hospitals reported HAIs to NHSN.
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TABLE 2.
Types of Pediatric Healthcare-Associated Infections (HAIs) and Surgical Site Infections (SSIs) Reported to the 
National Healthcare Safety Network, 2011–2014
Events Reported
(n = 20,390)
Pathogens Reported
(n = 22,323)
Type of HAI No. % No. %
CLABSI 14,074 69.0 15,538 69.6
CAUTI 2,150 10.5 2,366 10.6
VAP 1,226 6.0 1,366 6.1
SSI 2,940 14.4 3,053 13.7
SSIs SSI Pathogens
Type of Surgery No. % No. %
Abdominala 1,488 50.6 1,577 51.7
Breastb 2 0.1 2 0.1
Cardiacc 368 12.5 312 10.2
Kidneyd 1 <0.1 3 0.1
Neurologicale 486 16.5 491 16.1
Ob/Gynf 123 4.2 107 3.5
Orthopedicg 441 15.0 524 17.2
Transplanth 26 0.9 34 1.1
Vasculari 5 0.2 3 0.1
NOTE. CLABSI, central line-associated bloodstream infection; CAUTI, catheter-associated urinary tract infection; VAP, ventilator-associated 
pneumonia; SSI, surgical site infection; Ob/Gyn, obstetrical and gynecological.
aAppendectomy, bile duct, liver, or pancreatic surgery, gallbladder surgery, colon surgery, gastric surgery, herniorrhaphy, small bowel surgery, 
spleen surgery, abdominal surgery, and rectal surgery.
b
Breast surgery only.
cCardiac surgery, coronary artery bypass graft with chest incision with or without donor incision, pacemaker surgery, and thoracic surgery.
d
Kidney surgery only.
eCraniotomy and ventricular shunt.
fCesarean section, abdominal hysterectomy, ovarian surgery, and vaginal hysterectomy.
gOpen reduction of fracture, hip prosthesis, knee prosthesis, limb amputation, spinal fusion, refusion of spine, and laminectomy.
h
Heart transplant, kidney transplant, and liver transplant.
iAbdominal aortic aneurysm repair, shunt for dialysis, carotid endarterectomy, and peripheral vascular bypass surgery.
Infect Control Hosp Epidemiol. Author manuscript; available in PMC 2019 July 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lake et al. Page 13
TABLE 3.
Pediatric Surgical Site Infections (SSIs) Reported to the National Healthcare Safety Network, by Surgery 
Type, 2011–2014a,b
SSIs Reported
Surgery Type No. % No. %
Appendix surgery 682 23.2
Colon surgery 554 18.8
Ventricular shunt 429 14.6
Cardiac surgery 344 11.7
Spinal fusion 319 10.9
Cesarean section 101 3.4
Small bowel surgery 100 3.4
Exploratory Laparotomy 80 2.7
Craniotomy 57 1.9
Laminectomy 51 1.7
Open reduction of fracture 48 1.6
Bile duct, liver or pancreatic surgery 23 0.8
Liver transplant 20 0.7
Gastric surgery 18 0.6
Abdominal hysterectomy 16 0.5
Gallbladder surgery 15 0.5
Pacemaker surgery 15 0.5
Herniorrhaphy 9 0.3
Otherc 59 2.0
Total 2,940 100
aSurgeries with fewer than 15 SSIs reported are not shown, with the exception of herniorrhaphy.
b
Beginning in 2014, only surgeries with primary closure are included.
cOther includes hip prosthesis (n = 14, 0.5%), knee prosthesis (n = 7, 0.2%), ovarian surgery (n = 6, 0.2%), thoracic surgery (n = 6, 0.2%), 
abdominal aortic aneurysm repair (n = 5, 0.2%), kidney transplant (n = 5, 0.2%), rectal surgery (n = 5, 0.2%), coronary artery bypass graft with 
both chest and donor site incision (n = 3, 0.1%), breast surgery (n = 2, 0.1%), limb amputation (n = 2, 0.1%), spleen surgery (n = 2, 0.1%), heart 
transplant (n = 1, 0.03%), kidney surgery (n = 1, 0.03%).
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